Company profile
Cumulus Neuroscience Limited
Cumulus Neuroscience
Cumulus Neuroscience Limited is a UK company with status active founded in 2015 based in Northern Ireland.
Corporate ownership
Updated 06 Jun 2026 16:52
Company events
Reference milestones and recent Companies House filing stream events.
Accounts due
Accounts DueNext accounts due date
Confirmation statement due
Confirmation DueNext confirmation statement due date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Appoint Person Director Company With Name Date
OfficersAP01 | Transaction MzQzNjY4MTkwM2FkaXF6a2N4
Published 20 Sep 2024 11:14
Confirmation Statement With Updates
Confirmation-statementCS01 | Transaction MzQzNjY5OTYwOWFkaXF6a2N4
Published 20 Sep 2024 01:54
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Accelerating Alzheimer’s Diagnosis (AccelADx) to Enable Precision Clinical Trial Patient Stratification and Clinical Care using Neurophsyiological Biomarkers and AI
1 May 2024 to 31 Jul 2026
Alzheimer's dementia (AD) is a devastating disease for patients and their families, directly affecting almost 60M people today, expected to reach 139M by 2050\. It is a global problem, that needs a global solution. But the disease appears very gradually and can be hard to detect early. This means people can miss the opportunity to fully benefit from newer...
Optimising Blood Biomarker Accuracy for Clinical Trials and Healthcare using Artificial Intelligence and Digital Biomarkers
1 Dec 2023 to 30 Nov 2024
**The need for accurate early diagnosis** The 2022 World Alzheimer Report estimates that 55 million people globally are living with dementia, projected to rise to 139 million by 2050\. Early diagnosis tools are desperately needed, with diagnosis typically occurring late in the disease process and misdiagnosis common due to the overlap of cognitive symptom...
Cumulus NeuroScience: Real-World Technology to Accelerate Clinical Trials in Dementia
1 Mar 2021 to 30 Jun 2023
It is estimated that more than one million people in the UK will have dementia by 2025, with one in three born in 2015 projected to develop it in their lifetimes (ARUK, www.dementiastatistics.org). Clinical trials in this field are typically long, drug development costs are extremely high, and success rates for development of dementia treatments are excee...
Accelerating Value to an EEG-based solution for Remote Trials, during COVID-19 (AVERT COVID-19)
1 Jun 2020 to 30 Nov 2020
The global crisis caused by the COVID-19 pandemic has had a profound and widespread effect on healthcare. Priorities have necessarily shifted, and resources have been diverted to assist with the crisis. For many thousands of patients enrolled in ongoing or planned clinical trials, it is vital to maintain safety but also minimise, where possible, disruptio...
ANTONA-MH: Accelerating New Therapies with Objective Neurophysiological Assessment for Mental Health
1 Sep 2019 to 30 Nov 2021
Mental health conditions like depression and schizophrenia affect millions of citizens in the UK, and have consequences for their quality of life, as well as families and wider communities. One reason that mental health conditions are difficult to treat is that it is hard to diagnose them precisely, or to know when a possible treatment is working, as that...
In-home screening of cognitive ageing to enable improved patient outcomes
1 Jan 2017 to 31 Mar 2018
A novel neuroscience platform is proposed that allows anyone to directly measure and track their cognitive health in just a few minutes a day from the comfort of their home. This low cost approach will make quantitative, objective cognitive health tracking accessible to all and transform our understanding of brain health including how lifestyle, age, and ...